Galapagos NV (GLPG)

184.48
4.00 2.10
NASDAQ : Health Technology
Prev Close 188.48
Open 183.60
Day Low/High 183.02 / 185.20
52 Wk Low/High 85.00 / 192.89
Volume 109.58K
Avg Volume 128.90K
Exchange NASDAQ
Shares Outstanding 64.57M
Market Cap 11.86B
EPS -0.70
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMKR, BIIB, FEYE, GLPG, HSC, OSPN, PSMT, PTCT, SILC, THRM, TSLA, VNOM, ZEN Downgrades: ALOT, ATGE, AXS, CZR, EPR, HUN, NXPI, TCF, WAT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

HitGen Enters Into DNA-Encoded Library Based Drug Discovery Research Collaboration With Galapagos NV

HitGen Enters Into DNA-Encoded Library Based Drug Discovery Research Collaboration With Galapagos NV

HitGen Inc. today announced that it has entered into a drug discovery research collaboration with Galapagos NV to identify potential small molecule leads against targets of interest to Galapagos NV.

Gilead And Galapagos Announce Efficacy And Safety Results Of Filgotinib Through 52 Weeks In FINCH 1 And FINCH 3 Studies In Rheumatoid Arthritis

Gilead And Galapagos Announce Efficacy And Safety Results Of Filgotinib Through 52 Weeks In FINCH 1 And FINCH 3 Studies In Rheumatoid Arthritis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the...

Gilead And Galapagos Complete Closing Of Their Transformative Research And Development Collaboration

Gilead And Galapagos Complete Closing Of Their Transformative Research And Development Collaboration

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019.

European Medicines Agency Validates Marketing Application For Filgotinib For The Treatment Of Rheumatoid Arthritis

European Medicines Agency Validates Marketing Application For Filgotinib For The Treatment Of Rheumatoid Arthritis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with...

One Prescription for Uncertain Market? Gilead Sciences

One Prescription for Uncertain Market? Gilead Sciences

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

Will Gilead Sciences Stock Really Rally 33% From Here?

Will Gilead Sciences Stock Really Rally 33% From Here?

Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

Gilead Boosts Investment in Inflammatory Specialist Galapagos by $5.1 Billion

Gilead Boosts Investment in Inflammatory Specialist Galapagos by $5.1 Billion

Gilead Sciences said Monday that it will boost its stake in Belgian listed biotech Galapagos NV by more than $5 billion in a "transformative" deal that could tap new opportunities for the California-based group in fibrosis and arthritis.

Gilead And Galapagos Enter Into Transformative Research And Development Collaboration

Gilead And Galapagos Enter Into Transformative Research And Development Collaboration

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that they have entered into a 10-year global research and development collaboration.

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

Gilead And Galapagos To Present Latest Data On Filgotinib At The Annual European Congress Of Rheumatology (EULAR 2019)

Gilead And Galapagos To Present Latest Data On Filgotinib At The Annual European Congress Of Rheumatology (EULAR 2019)

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in...

Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint

Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint

The company's treatment, filgotinib, is being developed with Gilead Sciences.

Gilead And Galapagos Announce Filgotinib Meets Primary Endpoint In The Phase 3 FINCH 3 Study In Methotrexate-Naïve Rheumatoid Arthritis Patients

Gilead And Galapagos Announce Filgotinib Meets Primary Endpoint In The Phase 3 FINCH 3 Study In Methotrexate-Naïve Rheumatoid Arthritis Patients

regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced Week 24 results of FINCH 3, an ongoing, randomized, double-blind, active-controlled Phase 3 study of filgotinib, an investigational,...

Gilead And Galapagos Announce Filgotinib Meets Primary And Key Secondary Endpoints In The Phase 3 FINCH 1 Rheumatoid Arthritis Study

Gilead And Galapagos Announce Filgotinib Meets Primary And Key Secondary Endpoints In The Phase 3 FINCH 1 Rheumatoid Arthritis Study

regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced Week 24 results of FINCH 1, an ongoing, randomized, double-blind, placebo- and active-controlled Phase 3 study of filgotinib, an...

Gilead And Galapagos Report Updated Safety Information For Filgotinib In Rheumatoid Arthritis (RA)

Gilead And Galapagos Report Updated Safety Information For Filgotinib In Rheumatoid Arthritis (RA)

regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today also announced interim safety information from four studies of the investigational compound filgotinib for the treatment of rheumatoid arthritis...

Positive Trial Results With Filgotinib In Psoriatic Arthritis And Ankylosing Spondylitis Both Published In The Lancet

Positive Trial Results With Filgotinib In Psoriatic Arthritis And Ankylosing Spondylitis Both Published In The Lancet

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis...

Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis To Be Presented At 2018 ACR/ARHP Annual Meeting

Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis To Be Presented At 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely...

Gilead And Galapagos Announce Filgotinib Meets Primary And All Key Secondary Endpoints In First Phase 3 Study In Rheumatoid Arthritis

Gilead And Galapagos Announce Filgotinib Meets Primary And All Key Secondary Endpoints In First Phase 3 Study In Rheumatoid Arthritis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that FINCH 2, a global, randomized, placebo-controlled, Phase 3 study of filgotinib, an investigational, selective JAK1 inhibitor, in adults with...

Gilead And Galapagos Announce TORTUGA Phase 2 Study Of Filgotinib In Ankylosing Spondylitis Achieves Primary Endpoint

Gilead And Galapagos Announce TORTUGA Phase 2 Study Of Filgotinib In Ankylosing Spondylitis Achieves Primary Endpoint

Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV (Euronext & NASDAQ:GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint...

Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results

Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results

Galapagos' new cystic fibrosis drug trial results were weaker than expected.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

Galapagos Delivered In 2017

Galapagos Delivered In 2017

TheStreet Quant Rating: B (Buy)